IP Library Granted Patent US 10,934,284
Granted Patent B2
US 10,934,284 · App. 16/285,460 · Granted Mar 2, 2021

Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity

Inventors: David M. Simpson (North Bethesda, MD); Dennis Bryan Zerby (Chambersburg, PA); Ming Lu (Bethesda, MD); Reid W. Von Borstel (Potomac, MD); Rui Li (Darnestown, MD); Julian Reading (Frederick, MD); Stephen Wolpe (Boyds, MD)
Assignee: Wellstat Therapeutics Corporation
C07D471/04A01N43/42A01N43/50A01N43/54A01N43/60A01N43/90A61K31/337A61K31/40A61K31/4164A61K31/4184A61K31/437A61K31/44A61K31/4425A61K31/472A61K31/475A61K31/4706A61K31/4709A61K31/4745A61K31/498A61K31/4965A61K31/505A61K31/517A61K31/555A61K31/704A61P33/02A61P35/00C07D209/12C07D213/73C07D213/74C07D215/38C07D215/40C07D215/42C07D215/44C07D215/46C07D233/60C07D235/08C07D239/42C07D239/94C07D241/20C07D241/44C07D401/12Y02A50/409Y02A50/411Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,934,284
App. No.
16/285,460
Granted
Mar 2, 2021
Kind
B2
Abstract

Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.

Claims (15)

1. A compound represented by Formula IB1 or a pharmaceutically acceptable salt thereof

wherein n is 1;

Q is absent;

R 1 is hydrogen or halo; and

R 7 is phenyl substituted by alkoxy having from 6 to 10 carbon atoms or phenoxy.

2. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

N-[3-(Hexyloxy)benzyl]quinazolin-4-amine,

N-[3-(Decyloxy)benzyl]quinazolin-4-amine,

N-[4-(Decyloxy)benzyl]quinazolin-4-amine,

N-[4-(Hexyloxy)benzyl]quinazolin-4-amine.

3. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

4. The compound or salt of claim 1 , wherein the compound is N-(3-Phenoxybenzyl)quinazolin-4-amine.

5. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt of claim 4 and a pharmaceutically acceptable carrier.

6. A method of inhibiting a fungus ex vivo, comprising contacting a surface or the fungus with the compound or pharmaceutically acceptable salt of claim 1 .

7. A method of inhibiting a fungus ex vivo, comprising contacting a surface or the fungus with the compound or pharmaceutically acceptable salt of claim 4 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065349/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2023
From: SIMPSON, DAVID M.; ZERBY, DENNIS BRYAN; LU, MING; VON BORSTEL, REID W.; LI, RUI; READING, JULIAN; WOLPE, STEPHEN; AMAN, NUREDDIN
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 065217/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 064806/0515 →
Continuity (4)
Continuation 16015264 · Jun 22, 2018
Continuation 14764207
Provisional Application 61759512 · Feb 1, 2013
Related Publication 20190194193A1 · Jun 27, 2019
Cited By (1)
US 12,649,739